Sandbox: HS: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
! | ! | ||
! colspan="2" |History and Symptoms | ! colspan="2" |History and Symptoms | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!Estrogen-to-androgen ratio | !Estrogen-to-androgen ratio | ||
Line 20: | Line 18: | ||
!Age of onset | !Age of onset | ||
!Medication intake | !Medication intake | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Gynecomastia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Gynecomastia | ||
Line 26: | Line 23: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 37: | Line 34: | ||
|} | |} | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Physiological gynecomastia is seen in newborns, adolescents and elderly | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Pharmacological gynecomastia has hx of medication intake. | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pseudo gynecomastia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 56: | Line 53: | ||
|} | |} | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 64: | Line 59: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |+/-; mostly painless | | style="background: #F5F5F5; padding: 5px;" | +/-; mostly painless | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| | | | ||
* Usually painless mass | * Usually painless mass | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Middle age to elderly | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 79: | Line 73: | ||
| style="background: #F5F5F5; padding: 5px;" |'''↑''' | | style="background: #F5F5F5; padding: 5px;" |'''↑''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 90: | Line 84: | ||
|} | |} | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Middle age to elderly | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 99: | Line 92: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 109: | Line 102: | ||
|} | |} | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 126: | Line 117: | ||
* Systemic clinical features of infection. | * Systemic clinical features of infection. | ||
|} | |} | ||
| | | | ||
| | | |
Revision as of 18:18, 28 August 2017
Diseases | Laboratory Findings | Physical Examination | History and Symptoms | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Estrogen-to-androgen ratio | Cholesterol levels | WBC count | Tenderness | Enlargement | Nipple discharge | Lymphadenopathy | Other physical exam findings | Age of onset | Medication intake | ||
Gynecomastia | ↑ | +/- | + |
|
|
| |||||
Pseudo gynecomastia | +/- | + |
|
||||||||
Breast Cancer | +/-; mostly painless | + | + | + |
|
|
|||||
Lipoma | ↑ | +/- | + |
|
|
||||||
Sebaceous cyst | + |
|
|||||||||
Mastitis | + | Tender | +/- | +/- | +/- |
|
- This table must include the cardinal manifestations of differential diagnosis and the list of diseases must be prioritize based on mortality rate and prevalences of the diseases. For example, if you want to write a differential diagnosis table for heat stroke, sepsis, malignant hyperthermia, neuroleptic malignant syndrome, and serotonin syndrome first, you need to mention the cardinal manifestations for these conditions as, hyperthermia and altered mental status. Second, prioritize your list based on disease mortality or prevalence then, create the table. You can find the example here.
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Differential 1 |
|
|
Differential 2 |
|
|
Differential 3 |
|
|
Differential 4 |
|
|
Differential 5 |
|
|
Differential Diagnosis | Differentiating Features |
---|---|
Gynecomastia |
|
Pseudogynecomastia |
|
Lipoma |
|
Breast cancer |
|
Sebaceous cyst |
|
Mastitis |
|
ABC
def
DRUGS | MOA | SIDE | |
---|---|---|---|
SDFA | SDFA | DSFA | |
papichul
Based on the androgen and estrog imabalance | |
---|---|
Decreased testosterone | Increased estrogen |
Based on the androgen and estrogen balance
- Decreased Testosterone
- Androgen-insensitivity syndrome
- Congenital anorchia
- Five alpha-reductase deficiency
- Hypopituitarism
- Kallman Syndrome
- Klinefelter Syndrome
- Renal Failure
- Testicular trauma
- Torsion of the testes
- Viral orchitis
- Increased Estrogens
- Adrenal cancer
- Chronic liver disease
- Extragonadal germ cell tumors
- Familial gynecomastia
- Hyperthyroidism
- Kidney carcinoma
- Liver cancer
- Lung carcinoma
- Malnutrition
- Other gastrointestinal (GI) tract carcinoma
- Stomach cancer
- Testicular cancer
references
{{{ stimulatory action }}} | {{{ Breast Tissue }}} | Inhibitory action | |||||||||||||||||||||||||||||
Right coronary artery | Androgens | ||||||||||||||||||||||||||||||
Estrogen | Brachiocephalic a | R common carotid a | |||||||||||||||||||||||||||||
R subclavian a | |||||||||||||||||||||||||||||||
L common carotid a | Internal carotid a | ||||||||||||||||||||||||||||||
External carotid a | |||||||||||||||||||||||||||||||
L subclavian a | Axillary a | ||||||||||||||||||||||||||||||
Int. thoracic a | |||||||||||||||||||||||||||||||
Progesterone (Thorax) | Bronchial as | ||||||||||||||||||||||||||||||
Growth hormone and IGF-1 | Celiac a | L gastric a | |||||||||||||||||||||||||||||
Common hepatic a | |||||||||||||||||||||||||||||||
Splenic a | |||||||||||||||||||||||||||||||
SMA | |||||||||||||||||||||||||||||||
Renal as | |||||||||||||||||||||||||||||||